01—Abstract
Summary
Summary of the 8-K filed October 3, 2024. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2024, to provide preliminary updates on its third-quarter 2024 financial performance, specifically regarding acquired in-process research and development (IPR&D) and milestones expenses.
The company anticipates that these expenses will negatively impact both its GAAP and non-GAAP diluted earnings per share by approximately $0.04a on a pre-tax basis. This filing also revises AbbVie's full-year 2024 adjusted diluted earnings per share guidance to a range of $10.67 - $10.87, incorporating these newly accounted for third-quarter expenses. This disclosure is important for investors as it signals an unplanned increase in R&D-related expenses that affects profitability metrics.
While AbbVie typically does not forecast these specific types of expenses due to their unpredictable nature, the company is providing updated guidance to reflect their inclusion. Investors should note that these are preliminary estimates and the final results for the third quarter are subject to the company's financial statement closing procedures.
02—Key points
Key Highlights
- AbbVie anticipates $82 million in pre-tax acquired IPR&D and milestones expense for Q3 2024.
- This expense is expected to reduce both GAAP and non-GAAP diluted EPS by $0.04.
- Full-year 2024 adjusted diluted EPS guidance is revised to $10.67 - $10.87, including Q3 expenses.
- Q3 2024 adjusted diluted EPS guidance is updated to $2.88 - $2.92, reflecting these expenses.
- AbbVie does not typically forecast acquired IPR&D and milestones expenses due to inherent uncertainties.
- The provided figures are preliminary estimates and are subject to final financial closing procedures.
03—Questions
Frequently Asked Questions
What are acquired IPR&D and milestones expenses?
Acquired IPR&D and milestones expenses relate to costs incurred when AbbVie enters into collaborations, licensing agreements, or acquires other assets. These expenses are associated with research and development activities that have not yet reached regulatory approval.
Why is AbbVie reporting this now?
AbbVie is filing this 8-K to provide investors with an early update on the financial impact of these specific expenses, which were not previously forecasted. This allows for a more informed view of the company's expected quarterly and full-year financial performance.
How will this affect AbbVie's future guidance?
The full-year 2024 adjusted diluted EPS guidance has been updated to a range of $10.67 - $10.87 to incorporate the estimated Q3 acquired IPR&D and milestones expense. The Q3 guidance itself has also been revised to $2.88 - $2.92.
Are these final numbers for the third quarter?
No, these are preliminary estimates. The report states that results for the quarter ended September 30, 2024, have not been finalized and are subject to the company's financial statement closing procedures. There is a possibility that the final results may differ from these estimates.
04—Continue